SVA Share Price

Open 6.06 Change Price %
High 6.10 1 Day 0.02 0.33
Low 6.05 1 Week -0.01 -0.16
Close 6.10 1 Month -0.05 -0.81
Volume 88108 1 Year 0.16 2.69
52 Week High 7.16
52 Week Low 0.00
SVA Important Levels
Resistance 2 6.15
Resistance 1 6.13
Pivot 6.08
Support 1 6.07
Support 2 6.05
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
WRES 0.09 0.00%
SIRI 4.41 1.85%
QQQ 116.87 0.23%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ECTE 0.14 40.00%
BNSO 3.57 31.25%
FRAN 20.01 28.76%
FRAN 20.01 28.76%
FRAN 20.01 28.76%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
CRDS 5.45 25.87%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
IMRS 0.02 -33.33%
More..

Sinovac Biotech, Ltd. (NASDAQ: SVA)

SVA Technical Analysis 3
As on 6th Dec 2016 SVA Share Price closed @ 6.10 and we RECOMMEND Buy for LONG-TERM with Stoploss of 6.02 & Buy for SHORT-TERM with Stoploss of 6.02 we also expect STOCK to react on Following IMPORTANT LEVELS.
SVA Target for December
1st Target up-side 6.37
2nd Target up-side 6.55
3rd Target up-side 6.73
1st Target down-side 5.85
2nd Target down-side 5.67
3rd Target down-side 5.49
SVA Other Details
Segment EQ
Market Capital 148553632.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.sinovac.com
SVA Address
SVA
No. 39 Shangdi Xi Road
Haidian District
Beijing, 100085
China
Phone: 86 10 8289 0088
Fax: 86 10 6296 6910
SVA Latest News
Interactive Technical Analysis Chart Sinovac Biotech, Ltd. ( SVA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sinovac Biotech, Ltd.
SVA Business Profile
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is an integrated China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza and mumps, as well as animal rabies vaccine. The Company�s product pipeline also includes human vaccines against rotavirus, and human rabies that are in pre-clinical development. The Company specializes in the sales, marketing, manufacturing, and development of vaccines for infectious disease with unmet medical need. The Company�s pipeline consists of vaccine candidates in the clinical and pre-clinical development phases in China, including the EV71 vaccine and human vaccines for pneumococcal, rotavirus, rabies, varicella and rubella.